Mark C Blaser Selected Research

Fibrosis (Cirrhosis)

1/2023	Sortilin enhances fibrosis and calcification in aortic valve disease by inducing interstitial cell heterogeneity.
1/2018	Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark C Blaser Research Topics

Disease

9	Aortic Valve Disease 11/2023 - 08/2011
6	Atherosclerosis 01/2024 - 01/2019
5	Calcinosis 01/2021 - 05/2018
4	Inflammation (Inflammations) 07/2023 - 01/2020
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2024 - 12/2022
2	Heart Valve Diseases (Valvular Heart Disease) 11/2023 - 01/2022
2	Disease Progression 01/2023 - 01/2018
2	Fibrosis (Cirrhosis) 01/2023 - 01/2018
2	Aortic Valve Stenosis (Aortic Stenosis) 01/2021 - 01/2021
2	Left Ventricular Dysfunction 01/2021 - 01/2018
1	Heart Failure 01/2023
1	Carotid Stenosis (Carotid Artery Stenosis) 01/2023
1	Ventricular Remodeling 01/2023
1	Pathologic Constriction (Stenosis) 01/2023
1	Pathologic Processes 01/2023
1	Left Ventricular Outflow Obstruction 12/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Obesity 01/2021
1	Atherosclerotic Plaque (Atheroma) 01/2020
1	Hyperglycemia 01/2020
1	Bicuspid Aortic Valve Disease 01/2018
1	Hypertension (High Blood Pressure) 04/2011

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2018
3	MicroRNAs (MicroRNA)IBA 01/2024 - 01/2019
3	HydrogelsIBA 01/2020 - 05/2018
2	Lipoprotein(a)IBA 11/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2021
2	ProteomeIBA 01/2023 - 01/2018
2	CollagenIBA 01/2020 - 01/2019
1	LDL Lipoproteins (beta Lipoproteins)IBA 11/2023
1	EpitopesIBA 07/2023
1	sortilinIBA 01/2023
1	CalciumIBA 12/2022
1	LDL CholesterolIBA 12/2022
1	LipidsIBA 12/2022
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2022
1	Estrogen Receptor alphaIBA 01/2022
1	N 30IBA 01/2022
1	Collagen Type I (Type I Collagen)IBA 01/2022
1	prothymosin alphaIBA 01/2022
1	ApolipoproteinsIBA 01/2021
1	Apolipoprotein C-IIIIBA 01/2021
1	4- Acetamido- 4'- isothiocyanatostilbene- 2,2'- disulfonic Acid (SITS)IBA 01/2021
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2021
1	Streptozocin (Streptozotocin)FDA Link 01/2020
1	Apolipoproteins E (ApoE)IBA 01/2020
1	Annexin A1IBA 01/2020
1	Lipid NanoparticlesIBA 01/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	LigandsIBA 01/2019
1	Glial Fibrillary Acidic ProteinIBA 01/2018
1	Natriuretic PeptidesIBA 01/2018
1	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 08/2011
1	Antihypertensive Agents (Antihypertensives)IBA 04/2011

Therapy/Procedure

5	Therapeutics 01/2024 - 01/2018
4	Drug Therapy (Chemotherapy) 11/2023 - 01/2018
1	Secondary Prevention 12/2022